Therefore, we will review the prognostic and predictive value of EGFR/TP53 co-mutation in NSCLC patients, investigate the mechanisms of this co-mutation affecting the response to EGFR-TKIs, and further explore optimal regimens effectively to prolong the survival time the NSCLC patients harboring this co-mutation. Here, TP53 is linked to non-small cell lung carcinoma.